文献速递临床试验与 GCP流行病学与生物统计

SMAART试验:固定剂量多效复方制剂用于卒中二级预防的随机对照试验方案

Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment (SMAART): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-03-14

SMAART是一项在加纳近期缺血性卒中幸存者中开展的2期、开放标签、评估者盲法随机对照试验,计划纳入120例受试者,按1:1随机分为Polycap DS®干预组(每日一次两粒,含阿司匹林100mg、阿替洛尔50mg、雷米普利5mg、噻嗪类12.5mg、辛伐他汀20mg)与常规治疗组,随访12个月,主要结局为颈动脉内膜厚度逆转。

要点

  • 在撒哈拉以南非洲,卒中后二级预防的降压、他汀和抗血小板治疗启动与坚持常因后勤困难而难以实现。
  • SMAART评估固定剂量复方制剂Polycap DS®每日一次口服12个月对颈动脉内膜厚度逆转的作用。
  • 次要结局包括治疗依从性、安全性耐受性、健康相关生活质量、患者满意度、功能状态、抑郁和认知功能障碍。

核心结论

  • SMAART试验旨在评估含三种降压药、他汀和抗血小板药的固定剂量复方制剂每日一次口服12个月,相比常规治疗能否使近期卒中幸存者的颈动脉内膜厚度逆转。
  • 若试验提示有效,可为未来在撒哈拉以南非洲卒中幸存者中设计多中心、双盲、安慰剂对照、平行组随机对照试验比较复方制剂策略的临床疗效提供依据。

研究设计与样本

  • SMAART是一项2期、开放标签、评估者盲法随机对照试验,纳入120例加纳近期缺血性卒中幸存者。
  • 采用计算机生成序列按1:1将患者随机分配至干预组或常规治疗组,随访12个月。
  • 干预组接受Polycap DS®(含阿司匹林100mg、阿替洛尔50mg、雷米普利5mg、噻嗪类12.5mg、辛伐他汀20mg),每日一次两粒口服;常规治疗组由医生酌情处方个体化二级预防药物。
  • 主要结局为颈动脉内膜厚度逆转的变化,作为动脉粥样硬化的替代标志物。

关键数值与推荐

  • 主要结局指标为随访12个月时颈动脉内膜厚度逆转的变化。
  • 次要结局指标包括治疗依从性、安全性与耐受性、健康相关生活质量、患者满意度、功能状态、抑郁和认知功能障碍。
  • 试验注册于ClinicalTrials.gov,ID:NCT03329599,注册日期2017年2月11日。

临床怎么用

  • 该试验尚未报告结果,暂不能提供临床实践推荐;其设计针对撒哈拉以南非洲卒中后二级预防实施困难的场景。

局限性

  • 试验为2期、开放标签设计,样本量120例,主要结局采用颈动脉内膜厚度替代标志物,非临床硬终点。
  • 研究在加纳单国开展,结果外推至其他地区需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is an unprecedented rise in the prevalence of stroke in sub-Saharan Africa (SSA). Secondary prevention guidelines recommend that antihypertensive, statin and antiplatelet therapy be initiated promptly after ischemic stroke and adhered to in a persistent fashion to achieve optimal vascular-risk reduction. However, these goals are seldom realized in routine clinical care settings in SSA due to logistical challenges. We seek to assess whether a polypill containing fixed doses of three antihypertensive agents, a statin and antiplatelet therapy taken once daily per os for 12 months among recent stroke survivors would result in carotid intimal thickness regression compared with usual care (UC). METHODS: The Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment (SMAART) trial is a phase 2, open-label, evaluator-blinded trial involving 120 Ghanaian recent-ischemic-stroke survivors. Using a computer-generated sequence, patients will be randomly allocated 1:1 into either the intervention arm or UC. Patients in the intervention arm will receive Polycap DS® (containing aspirin, 100 mg; atenolol, 50 mg; ramipril, 5 mg; thiazide, 12.5 mg; simvastatin, 20 mg) taken as two capsules once daily. Patients in the UC will receive separate, individual secondary preventive medications prescribed at the physician's discretion. Both groups will be followed for 12 months to assess changes in carotid intimal thickness regression - a surrogate marker of atherosclerosis - as primary outcome measure. Secondary outcome measures include adherence to therapy, safety and tolerability, health-related quality of life, patient satisfaction, functional status, depression and cognitive dysfunction. DISCUSSION: An efficacy-suggesting SMAART trial could inform the future design of a multi-center, double-blinded, placebo-controlled, parallel-group, randomized controlled trial comparing the clinical efficacy of the polypill strategy for vascular risk moderation among stroke survivors in SSA. TRIAL REGISTRATION: ClinicalTrials.gov , ID: NCT03329599 . Registered on 11 February 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sarfo FS, Sarfo-Kantanka O, Adamu S, et al. Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment (SMAART): study protocol for a randomized controlled trial. Trials. 2018. PMID: 29540234. doi:10.1186/s13063-018-2564-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。